Chinese Journal of Respiratory and Critical Care Medicine
Supervisor：Ministry of Education of the People's Republic of ChinaSponsor：West China Medical Center & West China Hospital, Sichuan University Editor-in-chief：LIN Jiangtao / LIU Chuntao Publishing period：
Monthly
ISSN：1671-6205CN：51-1631/R
Citation：王長征. 2019GINA 更新：輕度哮喘治療的重要改變. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(6): 509-510. doi: 10.7507/1671-6205.201909060Copy
Copyright ? the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved
1.
O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med, 2018, 378(20): 1865-1876.
2.
Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med, 2018, 378(20): 1877-1887.
3.
Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med, 2019, 380(21): 2020-2030.
4.
Lazarus SC, Krishnan JA, King TS, et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med, 2019, 380(21): 2009-2019.
1. O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med, 2018, 378(20): 1865-1876.
2. Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med, 2018, 378(20): 1877-1887.
3. Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med, 2019, 380(21): 2020-2030.
4. Lazarus SC, Krishnan JA, King TS, et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med, 2019, 380(21): 2009-2019.
Click the content below to copy and paste a set citation format。
Citation：王長征. 2019GINA 更新：輕度哮喘治療的重要改變. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(6): 509-510. doi: 10.7507/1671-6205.201909060
1/5
WeChat